Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy
Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy News provided by Share this article Share this article PHOENIX, Dec. 10, 2020 /PRNewswire/ -- Creative Medical Technology Holdings trading under the ticker symbol CELZ announced t...
United States Timothy Warbington Thomas Ichim Exchange Commission University Of California Company Immcelz
Source: prnewswire.com